Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Sunil Godhwani...

    Sunil Godhwani responsible for Fortis Group woes: Singh Brothers Issue Statement

    Written by Ruby Khatun Khatun Published On 24 Aug 2018 11:06 AM  |  Updated On 24 Aug 2018 11:06 AM
    Sunil Godhwani responsible for Fortis Group woes: Singh Brothers Issue Statement
    Bloomberg has reported that Sunil Godhwani is the follower of the spiritual group, Radha Soami Satsang Beas and was appointed to lead Religare at the recommendation of the spiritual guru, Gurinder Singh Dhillon.

    New Delhi: Former promoters of Fortis Healthcare and Religare Malvinder Singh and Shivinder Singh blamed former Religare Enterprises Chairman and Managing Director Sunil Godhwani for the group's troubles.


    "The Group's troubles today stem from the Group's association with Sunil Godhwani who had started his association in Religare as its CEO in 2001," Malvinder Singh and Shivinder Singh said in a joint statement.


    Godhwani had stepped down as the chairman and MD in July 29, 2016. Subsequently, he assumed charge of the CEO in Religare Enterprises.


    After the Ranbaxy sale closed in 2008, it was decided that Godhwani will lead our family office in addition to his role in Religare, and from 2008-end, he had full management control of RHC Holding and its subsidiaries, it added.


    He was expected to be a responsible trustee and steward of the family's resources and consequently our reputation, the statement said.


    "Godhwani used his position to conceive and orchestrate a series of transactions over the better part of a decade that led to our Group's debt load by 2016," it added.


    It is clear that he used our trust in him to exercise undue influence and has taken advantage of the faith bestowed by both families, the statement said.


    "We are sure (Gurinder Singh) Dhillon and his family would have had a similar expectation from Godhwani regarding management of their resources," it added.


    Gurinder Singh Dhillon is the spiritual guru of the Radha Soami Satsang Beas (RSSB).


    Bloomberg has reported that Sunil Godhwani is the follower of the spiritual group and was appointed to lead Religare at the recommendation of the spiritual guru, Gurinder Singh Dhillon. They say Godhwani was also in charge of their holding company, RHC Holding Pvt., and often took decisions without informing them. They say he was the architect of the financial structures, including the loans to the Dhillon family and companies, that led to their financial troubles.


    Bloomberg News had been unable to independently verify the Singhs’ claims that Godhwani ran their holding company in the period between 2010 and 2016, when most of the major borrowing, loans, investments, and routing of funds occurred. RHC says he was president there between 2016 and 2017.


    Read also: The billionaires and the guru: A family burns through $2 billion

    Fortis HealthcareGurinder Singh DhillonMalvinder SinghRadha Soami Satsang Beas (RSSB).RanbaxyReligareReligare EnterprisesresponsibleRHC HoldingShivinder SinghSingh brothersspiritual guruSunil Godhwani
    Source : With Agency Inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok